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Abstract  
Background: Heterogenous outcome reporting in non-muscle-invasive bladder cancer (NMIBC) 
effectiveness trials of adjuvant intervention after transurethral resection (TURBT) has been noted in 
systematic reviews (SRs). This hinders comparing results across trials, combining them in meta-
analyses, and evidence-based decision-making for patients and clinicians. 
Objective: We aimed to systematically review the extent of reporting and definition heterogeneity.  
Methods: We included randomized controlled trials (RCTs) identified from SRs comparing adjuvant 
treatments after TURBT or TURBT alone in patients with NMIBC (with or without carcinoma in situ) 
published between 2000-2020. Abstracts and full texts were screened independently by two 
reviewers. Data were extracted by one reviewer and checked by another.  
Results: We screened 807 abstracts; from 15 SRs, 57 RCTs were included. Verbatim outcome names 
were coded to standard outcome names and organised using the Williamson and Clarke taxonomy. 
Recurrence (98%), progression (74%), treatment response (in CIS studies) (40%), and adverse events 
(77%) were frequently reported across studies. However, overall (33%) and cancer-specific (33%) 
survival, treatment completion (17%) and treatment change (37%) were less often reported. Quality 
of Life (3%) and economic outcomes (2%) were rarely reported. Heterogeneity was evident 
throughout, particularly in the definitions of progression and recurrence, and how CIS patients were 
handled in the analysis of studies with predominantly papillary patients, highlighting further issues 
with the definition of recurrence and progression vs treatment response for CIS patients. Data 
reporting was also inconsistent, with some trials reporting event rates at various time-points and 
others reporting time-to-event with or without Hazard Ratios. Adverse events were inconsistently 
reported. QoL data was absent in most trials.   
Conclusions: Heterogenous outcome reporting is evident in NMIBC effectiveness trials. This has 
profound implications for meta-analyses, SRs and evidence-based treatment decisions. A core 
outcome set is required to reduce heterogeneity. 
Patient Summary: Patients with non-muscle-invasive bladder cancer benefit from adjuvant 
instillation therapies. This systematic review found inconsistencies in outcome definitions and 
reporting, pointing out the urgent need for a core outcome set to help improve evidence-based 
treatment decisions. 
1. Introduction 
Description of the condition  
Bladder cancer is the 6th commonest male, and 17th commonest female cancer globally, with the 
highest incidence rates being observed in Europe and North America.1 The disease is categorised 
into two broad stage groupings, non-muscle invasive (NMIBC) and muscle-invasive (MIBC) bladder 
cancer. Most cases (75-85%) present as NMIBC and these patients typically have a higher long-term 
survival and a lower cancer specific mortality compared to those with MIBC.2   
NMIBC is defined as tumour(s) confined to the mucosa or invading the lamina propria.3 Using the 
TNM staging system, they are classified as Ta-T1 or Tis (or Cis) N0 M0.4  NMIBC tumours may be 
graded using the WHO 1973 or WHO 2004 grading systems – both indicating worse prognosis with 
increasing grade. Most patients diagnosed with NMIBC is initially treated conservatively (sparing the 
bladder) with curative intent by transurethral resection of bladder tumour (TURBT). NMIBC is seen 
as a chronic disease requiring frequent follow-up and repeated TURBTs, making it the most 
expensive of all cancers to treat from diagnosis to death 5–8 with additional productivity losses and 
informal care costs.9 Cumulative costs of care are especially high in intermediate- and high-risk 
NMIBC due to higher risk of  progression to MIBC requiring definitive treatment.7 
Given the high recurrence rates and the risk of progression to MIBC, NMIBC treatment usually 
involves adjuvant intravesical instillations with chemotherapy or immunotherapy. The timing, 
treatment duration, and choice of agent for intravesical therapy is guided by a risk categorisation 
system which is based upon clinical and pathological factors. 3 For instance, evidence from high 
quality systematic reviews and meta-analyses shows that a single immediate post-operative 
instillation of chemotherapy (IPOIC) is well tolerated and clinically effective in reducing recurrences 
in low risk patients. 10–12 The European Association of Urology (EAU)3  and the National Institute for 
Clinical and Healthcare Excellence (NICE) 13 both recommend that eligible patients receive IPOIC. It is 
considered cost effective for the NHS. 13  Intermediate risk patients may also be given repeated 
chemotherapy instillations, but their timing and frequency remains undefined14. It is recommended 
that high risk patients are treated with intravesical bacillus Calmette-Guerin (BCG) immunotherapy 
or be considered for immediate cystectomy.3 Five-year recurrence and progression rates for patients 
with stage Ta-T1 bladder cancer treated with 1 to 3 years maintenance BCG are 28-51% and 7-20%, 
respectively.15 
Why it is important to do this review 
Inconsistent outcome reporting (different outcomes in different trials) and variability in outcome 
reporting (same outcomes reported, but different definitions used) become acutely evident when 
many bladder cancer trials are included in systematic reviews of intervention effectiveness. 16–18 
Outcome reporting heterogeneity has been highlighted as a concern within evidence-based 
medicine generally, 19–22 and has been emphasised as an area for improvement in NMIBC trials by 
the International Bladder Cancer Group. 23 Heterogeneous outcome reporting and the potential for 
selective outcome reporting bias in NMIBC trials hinder comparing and contrasting the results of 
individual trials as well as the publication of unbiased systematic reviews and meta-analyses of the 
evidence base. As a consequence, making evidence-based recommendations in clinical practice 
guidelines, translating them into health care policy, and decision-making by clinicians and patients 
are all hampered.  
Developing core outcome set (COS) a solution to reduce outcome heterogeneity, selective outcome 
reporting bias, and helps to ensure that all trials contribute useable information to the evidence 
base. A COS is an agreed standardised collection of outcomes which should be measured and 
reported, as a minimum, in all trials for a specific clinical area. 22  Developing a COS is a solution to 
reduce outcome heterogeneity, selective outcome reporting bias, and helps to ensure that all trials 
contribute useable information to the evidence base. Our group has registered a bladder cancer COS 
development project (B-COS) with the Core Outcome Measures for Effectiveness Trials initiative COS 
register (http://www.comet-initiative.org/studies/details/1135), with the intent to create separate 
COS for three broad categories of disease: NMIBC, MIBC, and metastatic BC. Within each COS we 
define the scope with regards to the applicable populations and treatments. After defining the scope 
of a COS, the next step is to identify existing knowledge regarding outcomes. To meet this 
requirement, we have aimed to systematically review the outcomes reported in NMIBC 
effectiveness trials. Our systematic review protocol was registered with PROSPERO 
(https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=91820). The reviews for the 
other parts of the project will be reported separately as will the subsequent phases of the COS 
development projects, involving qualitative interview studies with patients, and consensus studies 
with key stakeholders such as patients and healthcare professionals using Delphi methods to come 
to consensus on the core outcomes to be measured in future bladder cancer effectiveness trials and 
audits.  
2. Methods 
Aims and objectives 
The aim was to systematically review outcomes reported in NMIBC effectiveness trials of adjuvant, 
prophylactic treatment after TURBT. 
The objectives were to systematically review:  
 
1. Outcomes reported 
2. Outcome definitions (including time points) 
3. Outcome assessment methods 
Eligibility Criteria  
Types of studies  
We included phase III randomised controlled trials (RCTs) comparing different adjuvant instillation 
treatments after TURBT or trials with TURBT alone as a control arm. We limited to RCTs included in 
systematic reviews of intervention effectiveness as a pragmatic and efficient way to identify studies 
and overview potentially important outcomes. This is a strategy that has been used in published 
systematic reviews of outcome reporting heterogeneity where the aim is to overview outcome 
reporting heterogeneity rather than to find every outcome previously reported.22,24 All pre phase III 
trials and all non-randomised designs were excluded. Studies reported only as abstracts were 
excluded a priori because it was unlikely that all outcomes would be reported in the abstract, and 
that they would also not provide enough information on the definition and measurement of 
outcomes reported.   
Types of participants  
We included studies with adult (≥18 years) males and females with histologically confirmed 
urothelial NMIBC, stage Ta or T1 N0 M0, with or without carcinoma in situ (CIS), and all tumour 
grades (using any grading system). Studies including paediatric patients and patients with MIBC, 
clinical N+ or M+ were excluded unless outcomes were separately reported and defined for NMIBC 
patients. 
Types of interventions and comparators 
We included RCTs comparing any type of intravesical adjuvant prophylactic treatments after TURBT 
and RCTs comparing intravesical treatment after TURBT versus TURBT alone. Studies of oral vitamins 
or mineral supplements were excluded.  
Types of Outcomes  
We report on all outcomes related to clinical effectiveness including, for example, outcomes related 
to recurrence, progression, survival and cause of death, local and systemic adverse events and 
quality of life/patient reported outcomes. Outcome definitions, timepoints, and assessment 
methods are also reported.  
We do not report any estimates of treatment effect for any individual trials and there was no 
attempt to synthesise aggregated quantitative data.   
Literature Search 
The literature search was undertaken by an experienced information specialist (CY) using the search 
criteria specified in Appendix 1. Medline, Embase and Cochrane Database of Systematic Reviews 
(CDSR) were searched for relevant systematic reviews. We also hand-searched the reference 
sections of relevant international clinical practice guidelines. We restricted to systematic reviews 
and RCTs published after 2000 to reflect outcomes reported in the current clinical practice. We 
excluded non-English studies as a pragmatic consideration due to resource restrictions.   
An update search was done on 15th January 2020.  
Data collection and analysis 
Selection of studies 
Following de-duplication, at least two review authors (DC, SM, SS, IO, EV, RC) independently 
screened the titles and abstracts of identified systematic reviews for eligibility. The full texts of all 
potentially eligible publications were retrieved and screened independently by two review authors 
(DC, SM, SS, IO, EV, RC) using a standardised form, linking together multiple records of the same 
study in the process. Any disagreements were resolved by discussion or by consulting a senior 
review author (RS). Once the list of systematic reviews meeting the inclusion criteria were finalised, 
a second screening process was initiated whereby the studies included in the systematic reviews 
were screened against our inclusion criteria. Where lists of studies excluded from the systematic 
reviews were available, we also screened these in case the studies had been excluded for not 
reporting on outcomes of interest. In such instances the trial may still have met inclusion criteria for 
our review. The study selection process is described in the PRISMA flow diagram (Figure 1).25   
Data extraction and management  
A standardised data extraction form was developed and piloted. One review author extracted data 
and a second review author checked data extractions for accuracy (DC, SM, SS, IO, EV, RC). Any 
disagreements were resolved by discussion or by consulting a third review author.  
Data that were extracted included: the study design; countries and institutions where the data were 
collected; dates defining start and end of patient recruitment and follow-up; how intervention 
comparator groups were formed; participant demographic and clinical characteristics; eligibility 
criteria for participants; the numbers of participants who were included in the study, assigned to 
each intervention comparator group; description of interventions; study funding sources; and ethical 
approval. All primary and secondary effectiveness outcomes reported, their definitions, and any 
outcome measurement instruments used were extracted verbatim. 
Assessment of risk of bias in included studies   
Risk of bias assessment is not necessary for systematic reviews undertaken for COS development. 
Some outcomes may be at risk of detection bias depending on whether they are relatively subjective 
or objective. Although these aspects were extracted under the ‘definition’ or ‘measurement’ fields in 
the data extraction form, this is out of the scope of this phase of our project. They will be 
investigated in a subsequent phase whereby we will assess the psychometric properties of the 
various outcome measurements and seek consensus on the most appropriate and feasible 
definitions and measurements. 26,27  
Data synthesis 
Verbatim outcome names were recoded to common names. This was done by categorising 
outcomes referring to the same underlying constructs under a common term. For example, “survival 
rates”, “overall survival”, “number of deaths at median follow up” and “mortality rate” all refer to 
the concept of ‘overall survival’ and were coded as such. The outcome and domain coding process 
was inductive and iterative. Coded outcomes were further grouped in broader domains using the 
standardised Williamson and Clarke Taxonomy (W/C Taxonomy). 28  
3.0 Evidence synthesis 
Characteristics of the included studies 
Our initial search for relevant systematic reviews yielded 807 abstracts, of which 639 remained after 
removing duplicates. In total, 100 full-text SRs were assessed and 19 SRs, including 14 meta-
analyses, were included. Four SRs included only previously identified RCTs and these SRs were not 
utilised further (Supplemental table 1). From 15 SRs published between years 2010-2018, 106 full-
texts of RCTs were screened and 57 eligible RCTs were finally included (see PRISMA flow diagram, 
Fig. 1).  
An overview of the included studies’ populations, stage and grade, instillation treatments and 
number of outcome domains reported is shown in Table 1.  Overall, 32 studies included patients 
with papillary only tumors, while 25 studies included a mixed population of patients with CIS 
with/without papillary tumors. There were 11 “single-instillation” trials, 12 “single instillation 
followed by induction course” trials, 27 “maintenance instillation” trials and 7 trials comparing 
instillations with different schedules.  
In all studies, patients were followed up at regular intervals in the same and largely accepted 
manner: urinary cytology, cystoscopy and if necessary, by taking biopsies from the urinary bladder.3 
 
 Heterogeneity in outcome reporting, detection, and definitions 
The outcomes were organised into the 10 domains in the W/C taxonomy [27]: “recurrence”, 
“progression”, “treatment response” (for CIS), “cancer-specific survival”, “overall survival”, “adverse 
events”, “completion/adherence”, “treatment failure/change of treatment”, “quality of life” and 
“health economics” (Table2). 
As seen in Table 2, tumor related outcomes such as recurrence (98%), progression (74%), treatment 
response (in CIS studies) (40%), and adverse events (77%) were frequently reported across studies. 
However, overall (33%) and cancer specific (33%) survival, treatment completion (17%) and 
treatment change (37%) were less often reported. Quality of Life (3%) and economic outcomes (2%) 
were rarely reported. 
Tumor related outcomes 
The heterogeneity in the definition and reporting of recurrence and progression in studies that 
recruited patients with papillary tumors only, and also treatment response in patients with CIS with 
or without papillary tumors, are shown in Tables 3 and 4, respectively. 
 
Recurrence 
Recurrence was reported in 56 (98%) of 57 trials (Tables 1,3,4), with 35 different verbatim names 
(Table 5), often related to the definition. The definition of recurrence was missing in 8/56 (14%) 
studies and in the others, variations of the percent of recurrences at a given time point or as a time 
to event outcome were used, but no consistent way of defining and measuring recurrence was used 
overall. Furthermore, in studies that reported both progression and recurrence, progression as the 
first event was regarded as a recurrence event in 12 studies and in 34 others it was not.  
Progression 
Of 57 studies, 42 (74 %) reported bladder cancer progression. Definition for progression was given in 
41/42 (97%) studies with a large variability in definition. A common threshold for “progression” was 
≥pT2 in 16 (38%) studies, with 2 of them also classifying CIS as a progression. As an example of 
inconsistency in verbatims used, “progression to MIBC” was used in the definition in 31/42 (74%) 
studies, with 22 of those further including metastases. Ta->T1 and T1->MIBC were considered 
progression in 4/42 (9%) studies (Tables 3 and 4).   
Treatment response 
Treatment response in patients with CIS was reported in 10 (40%) of 25 studies (Table 2). There was 
heterogeneity in what time-point was considered to assess the response to treatment. de Reijke et 
al defined and reported “complete response”, “partial response”, “no change” and “progression”.29  
The rest of the studies reported only complete response to treatment. 
 
The time-point to assess complete response varied largely, ranging from 3 months from enrollment 
up to 12 months.  
  
Eight different outcomes were included in the “Treatment response (for CIS)” domain (Tables 4 and 
5).  
Treatment relapse after complete response was described in three trials (Table 4). 
Death 
A survival outcome was reported in 44/57 (40%) of studies; equally common were cancer-specific 
survival and overall survival, each reported in 19 (33%) studies. Ten and eleven different verbatim 
names were used to report overall survival and cancer-specific survival, respectively (Tables 2, 5).  
 
Adverse events 
Adverse events (AEs) were heterogeneously defined. In 12 of the 44 studies (27%) reporting AEs, 
there was no definition of an AE, and overall 24 different definitions/instruments were used. Studies 
reporting AEs used unique systems to categorise the type of AE or grade the severity of the AEs, and 
made no reference to a standardised reporting system. Across 10 studies, 3 standardised AE 
reporting instruments were used, but these did not include some of the most relevant AEs for 
intravesical instillations: 
o NCI-CTCAE (Common Terminology Criteria of Adverse Events),  
o WHO toxicity grading scale,  
o WHO-ART (1979 WHO Adverse Reaction Terminology)  
Adverse events were further grouped in numerous ways, e.g. local or systemic toxicity, 
constitutional symptoms, laboratory abnormality, death, and treatment interruption due to AEs 
(Table 5). Detailed lists of how AEs were described and reported are provided in Supplementary 
table 2.  
In 25 of the 44 studies (57%) specific AEs were not listed; instead, authors reported either only local 
toxicities, or major/severe/more common side-effects or AEs that resulted in treatment 
interruption. Five of these 25studies did not report the list of individual toxicities at all; instead, 
authors presented only the frequency and percentage [n (%)] of any AEs which occurred. 
Furthermore, poor treatment compliance related to AEs was not consistently reported.  
 
Completion/adherence 
Adherence to completion of all planned instillations was at least partially reported in 10/57 (17%) 
studies: six studies concerning maintenance instillations, two “induction course” studies, and two 
studies comparing induction to maintenance. None of the single-instillation studies reported 
completion rates. Four studies gave a comprehensive overview of the reasons for treatment 
discontinuation. The author definitions for instillation treatment completion are reported in Table 5. 
 
Treatment failure/change of treatment  
21/57 studies (37%) reported treatment failure and/or the need to change from instillations to a 
different treatment. 21 studies specified the treatment that was given after instillations were 
discontinued: 
• radical cystectomy (RC) (14/21 studies) 
• RC and/or radiotherapy (RT) (4/12 studies) 
• TURBT (1/21) 
• RC, TURBT+RT, chemotherapy (1/21) 
• “non-allowed instillations” (1/21) 
 
Global quality of life 
Two studies measured and reported patient experience during the instillations; Koga et al by 
measuring Qol, and Huang et al by evaluating instillation related pain/irritation.30,31 
In the study by Koga et al, Qol was assessed according to the Japanese version of the European 
Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC 
QLQ-C30) v2.0. QoL was assessed before induction therapy, after the 5th instillation of induction 
therapy, 4 weeks after the completion of induction therapy, and 14 months after randomization.30 
Huang et al evaluated the effect of hyaluronic acid in reducing pirarubicin instillation related side-
effects. A visual analog scale (VAS) was used daily to evaluate pain.31 
 
Resource use (health economics) 
Only one study evaluated the costs related to the treatment. Berrum-Svennung et al randomized BC 
patients to one instillation of epirubicin or placebo after TURBT and evaluated cancer recurrences. 
They also calculated the cost of delivering a single instillation during the initial treatment and as first 
recurrences occured.32  
 
Discussion  
This is the first study to systematically and comprehensively overview the extent of outcome 
reporting, measurement, and definition heterogeneity in the setting of adjuvant treatments for 
NMIBC.  
Recurrence was frequently reported in the included RCTs; yet, some studies did not define it. In 
those that did, there was variability in the names that were used (for example “disease-free 
interval”, “disease-free survival”, “time to recurrence”, and “recurrence free survival”), the 
definitions and the reporting, with some reporting hazard ratios or median time to event, or event 
rates at inconsistent time points (e.g. 1,2,3,5,10 years). Most concerning, however, was the variation 
in how progression was handled in the analysis of recurrence. In studies where progression as the 
first event was counted as a recurrence, the measure provided is qualitatively and quantitatively 
different from those where recurrence was more narrowly defined as the re-appearance of a non-
muscle invasive tumour. To overlook this subtlety runs the risk of not comparing like with like across 
studies, or statistically pooling aggregated results in a potentially misleading way.  
Progression was also frequently reported, but again the definitions were inconsistent across trials, 
with some using progression to MIBC as the threshold, while others considered an increase in stage 
from Ta-T1 and/or an increase in grade as progression. Worsening of the disease leads to a change in 
treatment strategy, and that was also inconsistently reported. It is also crucial to point out whether 
assessment of progression has been made based on imaging (e.g. CT or MRI), TURBT or radical 
cystectomy. As only four studies gave a comprehensive overview of reasons to change the treatment 
strategy, there is a high risk of getting misleading results. If prior to progression, patients die due to 
an unrelated cause, or undergo cystectomy (for example due to recurrent high grade T1 disease), 
then the progression rates at specific time points will be different according to whether the death 
and cystectomy have been counted as a competing risk (cumulative incidence function) or simply as 
censored (Kaplan-Meier curve). Equally important is to highlight how patients are followed for the 
efficacy outcomes in case the treatment has been stopped due to side-effects. There may also be a 
difference in outcomes according to whether the results are reported in all randomized patients 
(intent to treat analysis) or only in eligible patients who have been treated according to the protocol 
(per protocol analysis). 
Treatment response in patients with CIS in specific was evaluated and reported in only 40% of 
studies. The rest of the studies recruiting patients with CIS considered CIS as papillary tumors, and 
reported only recurrence or/and progression. However, CIS additional diagnostic challenges and may 
have a very different disease course than papillary tumors do: as such, separate approaches to 
measure and define their outcomes should be applied.23  
The most heterogenous outcome was AEs, evident in the many categorizations and instruments 
used to record AEs, and in the system level subgroupings chosen by trialists. Unfortunately, many of 
these were not optimal for instillation-related AEs. Whilst in some instances it may be possible for 
systematic reviewers to recode lists of AEs (if they are provided) to a common standardized toxicity 
classification system, this is a poor excuse for lack of standardization in primary trials and needlessly 
adds time and complexity to the critical interpretation of the evidence base. Poor treatment 
compliance reporting is likely to confound other cancer related outcomes such as recurrence, 
progression and overall survival.  
Perhaps the most alarming finding is that QoL is conspicuously missing. Instillation treatments are 
demanding for patients and it would be very important to understand all the consequences (both 
oncological and QoL-related) for patients before the decision about treatment is made. A recent 
investigation of QoL in bladder cancer patients compared to a matched sample of older adults 
without bladder cancer in a US population found significant declines in health-related QoL (HRQoL) 
scores over time in the physical, mental and social components of the SF-36.33  The EORTC Quality of 
Life Group also developed an externally validated QLQ-BLS24 questionnaire for NMIBC. 34  In a 
systematic review, Mason and colleagues used the COSMIN checklist to evaluate the psychometric 
properties of PROMs used in bladder cancer populations, of which two of the 15 included PROMs 
were NMIBC-specific (QLQ-BLS24 and CAVICAVEMNI).35,36 Of note, they found that no existing PROM 
stood out as the most appropriate measure of QoL in any bladder cancer populations and although 
further validation studies are required generic PROMs, cancer-generic PROMs and bladder cancer-
specific PROMs will currently provide the most robust picture . This is a very important study to a 
subsequent phase of our COS development as most existing cancer COS have included QoL and it is 
anticipated NMIBC patients will also prioritise this, encompassing urinary, bowel and sexual 
function, as a critically important outcome domains.  
Without having included NMIBC patients in a qualitative study of their experiences of bladder cancer 
and its treatments, it cannot yet be known which outcomes are of most importance to them, or if 
they are adequately captured in current trials, but it is discouraging that so few trials routinely 
include patient reported outcome measures (PROMs).  
Health economics was considered in only one RCT, which calculated costs of single instillation.32 
Bladder cancer, especially NMIBC, contributes significantly to healthcare costs due to intense 
surveillance strategies and its potential to recur and progress.8,37 This should be considered when 
treatments and outcomes are compared. 
Kamat et al provided recommendations on NMIBC intervention trial designs, eligibility criteria, and 
‘clinically meaningful’  effect size thresholds for outcomes.23 Likewise, Lamm et al suggested a 
change in definition for progression in NMIBC.38  These initiatives are important to bear in mind for 
subsequent phases of our project. Once the outcomes considered core by all stakeholders (e.g. 
patients, urologists, oncologists, nurses, payers, methodologists) are known (i.e. what to measure)22 
then we will turn attention to definitions and measurement tools (i.e. how to measure)39 whilst 
again including key stakeholders. Importantly, these initiatives, in conjunction with ours, show that 
there is an acknowledgement of problems with the evidence base and a desire to do improvements. 
 
Limitations 
The decision to exclude phase I and II trials (phases before determining the therapeutic effect of the 
drug) and to exclude all non-randomised designs may have limited the chance to capture longer-
term and patient reported outcomes relating to function and QoL. However, in subsequent phases 
of the project, such as in Delphi survey and consensus meetings, participants will have an 
opportunity to propose ‘new’ outcomes not already considered for prioritisation, therefore we 
consider that the risk of having missed outcomes is minimal, and that we have carried out a 
pragmatic trade-off against the resource implication of including all study designs. 
 
Conclusions 
We have shown that there is inconsistency in outcome reporting and variation in definitions in 
randomized trials comparing adjuvant treatments in NMIBC patients. This situation makes 
comparing the results of individual studies difficult, and makes their statistical combination 
challenging, impossible, or inappropriate; hence, providing summaries of the evidence which are, at 
best, unwieldy and at worst misleading, making evidence-based treatment recommendations 
difficult. A core outcome set, incorporating the views of a variety of stakeholders such as urologists, 
oncologists, methodologists and, most importantly, patients, is urgently required.  
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Drug induced cystitis (bacterial cystitis, chemical cystitis)
Cystitis-like symptoms
Stranguria with or without cystitis
Frequency
Frequency (more than once per hour)


























Mild storage symptoms (dysuria, urgency, frequency)
Gross haematuria

















Bladder perforation requiring bladder-wall repair
Bladder irritation 
Irritative bladder symptoms
Irritative bladder symptoms (micturition pain and frequency 
of urination) 
Symptoms of irritated bladder
Pain during sessions
Bladder pain between sessions
Bladder pain during sessions
Bladder pain
urethral strictures (most likely repeat TURBTs)












Sense of residual urine
Other local side effects
Epididymitis
necrotizing granulomatous epididymitis 
prostatitis
granulomatous prostatitis

































polyneuropathy with axonal demyelination
dissemination of Mycobacterium bovis BCG with consecutive 
infiltration of a granuloma into the external carotid artery, 
which required immediate surgical intervention.
Accidental dose of MMC in TUBR and bladder perforation, 






fever of > 38 ° C 
high fever (>39°C)
fever  ≥39C
high-grade fever, high fever
fever (<39°C or >39°C) 
temperature >37.5°C
recurrent fever of 39°C or higher
fever and chills




















Abnormal clinical laboratory tests
hematologic abnormality 
Haematologic toxicity (Leucotytosis)





Elevation in serum transamylase level






Urinalysis (Urinary protein positive, Microscopic haematuria, 
Urinary red blood cell increase, Urinary white blood cell 
increase)
Death due to toxicty
Treatment related death
Death due to serious adverse event
death
low grade high grade low grade high grade
Lamm 2000 x x x x
Palou 2001 G3 G3
Au 2001 x x x x




Di Stasi 2003 x x




de Reijke 2005 x x x x
Di Stasi 2006 G2G3
Gårdmark 2007 x x x x
Cai 2008 G2G3 G2
Neple 2010 x x x x
Porena 2010 G3 G3
Koga 2010 x x x
Gülpınar 2012 x x x x
Järvinen 2012
Sengiku 2013 x x x x
Inamoto 2013 x x x x




G1G2+cis G3 G1G2+cis G3
Solsona 2015 G1+cis G2G3 G1 G2G3
Arends 2016 x x x x
Nakai 2016 x x x x
Kaasinen 2000 G1G2 G1G2
Bilen 2000 x
Van der Meijden 
2001
x x x x
Nomata 2002 G1G2 G1G2
Okamura 2002 x x x x
Rajala 2002 x x x x
Kuroda 2004 G1G2 G1G2
Koga 2004 x x x x
Mitsumori 2004 x x x x
Cheng 2005 x x x x
Vijjan 2006 x x x x
Hinotsu 2006 x x x x
























Ojea 2007 G2 G1G2
El-Ghobashy 2007 G1G2 G1G2
Agrawal 2007 x x x x
Friedrich 2007 x x x x




Isbarn 2008 x x x x
Böhle 2009 x x x x
Gudjonsson 2009 G1G2 G1G2
Järvinen 2009 x x x x
Seretta 2010 G1G2 G1G2
Sylvester 2010 x x x x
De Nunzio 2011 G1G2
Di Stasi 2011 x x x x
Hinotsu 2011 x x x x
Oddens 2013 x x x x
Huang 2015 x x x x
Onishi 2017 G1G2 G1G2













x x M 7
x x M 6
x x I 2
x x x I 5
x x I 7
x x M 7
x x x M 5
x x I 4
x x x M 5
x M 6
x x M 4
x M 4
x x M 2
x x M 3
x M 5
x x I 4
x x x M 5
x x x I 3
x x x I 4
x I 5
x M 4
x I vs M 5
x x I 5
x x x M 4


































































Quality of life Health Economics
Lamm 2000 x x x x x x x
Palou 2001 x x x x x x
Au 2001 x x
Sekine 2001 x x x x x
Martinez-Pinneiro 
2002
x x x x x x x
Di Stasi 2003 x x x x x x x
Kaasinen 2003 x x x x x
Martinez-Pinneiro 
2005
x x x x
de Reijke 2005 x x x x x
di Stasi 2006 x x x x x x
Gårdmark 2007 x x x x
Cai 2008 x x x x
Neple 2010 x x
Porena 2010 x x x
Koga2010 x x x x x
Gülpınar 2012 x x x x
Järvinen 2012 x x x x x
Sengiku 2013 x x x
Inamoto 2013 x x x x
Rentsch 2014 x x x x x
Hemdan 2014 x x x x
Martinez-Pineiro 
2015
x x x x x
Solsona 2015 x x x x x
Arends 2016 x x x x
Nakai 2016 x x x x x
Kaasinen 2000 x x NA x
Bilen 2000 x x NA x x
Van der Meijden 
2001
x x NA x x
Nomata 2002 x NA x
Okamura 2002 x x NA x
Rajala 2002 x NA
Kuroda 2004 x NA x x x
Koga 2004 x NA x
Mitsumori 2004 x NA x
Cheng 2005 x x NA x x x
Vijjan 2006 x x NA x x x
Hinotsu 2006 x x NA x
Barghi 2006 x x NA x
Ojea 2007 x x NA x x
El-Ghobashy 2007 x x NA x
Agrawal 2007 x NA x
Friedrich 2007 x NA x
Hendricksen 2008 x x NA x
Berrum-Svennung 
2008
x x NA x
Isbarn 2008 x NA x
Böhle 2009 x x NA x x
Gudjonsson 2009 x NA
Järvinen 2009 x x NA x x x
Seretta 2010 x x NA x
Sylvester 2010 x x NA x x x x
De Nunzio 2011 x x NA x x
Di Stasi 2011 x x NA x x x
Hinotsu 2011 x x NA x x
Oddens 2013 x x NA x x x x
Huang 2015 x NA x x x
Onishi 2017 x x NA x
Bijalwan 2017 x x NA x










































Kaasinen 2000 x x
Bilen 2000 x x
Van der Meijden 2001 x x x
Nomata 2002 x
Okamura 2002 x
Rajala 2002 x x
Kuroda 2004 x x
Koga 2004 x x x
Mitsumori 2004 x x
Cheng 2005 x x
Vijjan 2006 x x
Hinotsu 2006 x x x
Barghi 2006 x
Ojea 2007 x x x
El-Ghobashy 2007 x x
Agrawal 2007 x
Friedrich 2007 x x x x




Isbarn 2008 x x x
Böhle 2009 x x
Gudjonsson 2009 x x x
Järvinen 2009 x x
Seretta 2010 x x x x x
Sylvester 2010 x
De Nunzio 2011 x
Di Stasi 2011 x x
Hinotsu 2011 x x x
Oddens 2013 x x 5yr DFR
Huang 2015 x x x
Onishi 2017 x x x
Bijalwan 2017 x x

















































≥pT2, cis x x x x
x
x
≥pT2 x x x
≥pT2 x x
≥pT2 x x x
≥pT2 x
≥pT2 x x x
≥pT2 x x x x









rate at the 



































No Cis, no 
Ta/T1
at 9 mo no 
progressio












Lamm 2000 x x
Palou 2001
Au 2001
Sekine 2001 x x
Martinez-Pinneiro 2002
Di Stasi 2003 x
Kaasinen 2003 x
Martinez-Pinneiro 2005
de Reijke 2005 x x








































x (for cis pts) x














































T-stage Grade MIBC Metastases
≥pT2







































































the first event 
included as 
recurrence?
median time to first recurrence
time to initial recurrence
early recurrence (0-2 years)










recurrence rate and recurrence free rate at 
different timepoints: 1,2,3,5, 10yrs
incidence of recurrence
probability of recurrence at 5,10 and 15 yrs
Recurrence risk (at 3 year and 5 year)
NMIBC recurrence (pTa,pT1)
Type of recurrence (cis, papillary Ta/T1 or 
grater than T1)
recurrence rate per year
tumor per year rate





Tumor size of first recurrence
Recurrence-free rate
Time to recurrence












Time to first progression Overall survival
Time to progression in stage Overall mortality
Time to progression to MIBC Survival
Time to progression in grade Cancer deaths
Time to progression to distant metastasis Death
Time to distant metastasis Survival time
5-year overall survival
5-year progression-free survival Time to death by any cause
Progression-free at 5 years Duration of survival
Worsening free survival Causes of deaths
Progression-free time




Rate of progression to T2 or grater










Death from bladder cancer
Cancer-specific survival time
















CTCAE v3.0 (Common Terminology Criteria of 
 NCI-CTC v2.0 (National Cancer Institute-Common 
 WHO toxicity grading scale
WHO-ART (1979 WHO Adverse Reaction Terminology 
into 4 classes (I to IV); (class I—related symptoms, 
l  II d  t  d l  III d 
TREATMENT RESPONSE (for cis)
complete response rate
complete response at 3 months and 1 year
response to treatment
efficacy of induction therapy
number of instillations need to achieve a complete response
complete response rate in patients with CIS or concomitant carcinoma in situ (pTa or pT1)
treatment efficacy in patients with CIS
overall complete response rate
DEFINITIONS FOR INSTILLATION TREATMENT COMPLETION 
completion rate (all planned instillations in the cycle were administered) 
performance rate (at least one of the three planned instillations in the cycle was administered) 
completion and performance rate at 3, 6, 12 and 18 months
% of patients that received all 8 scheduled courses during 3 years
% of patients completed the planned 2-year programmed treatment
% of patients that received maintenance  therapy for 6 months and 18 months
the mean number of instillations
number of patients receiving 6-11 instillations
number of patients receiving < 6 instillations
number of patients  received induction treatment
maintenance (long-term arm): number of patients complete six instillations and also 1 yr, 2 and 3 yr   
median number of instillations
probability of non-cessation of instillations (%) at 6, 12 and 15 months
number of patients received at least 4 instillations as induction course
number of patients that received fewer than the planned 28 instillations of the protocol
                 of maintenance therapy
